Management of Hypertension, Tachycardia, and Chronic Kidney Disease

Initial Management

The American College of Cardiology recommends initiating an ACE inhibitor (or ARB if not tolerated) as first-line therapy targeting blood pressure <130/80 mmHg, adding a beta-blocker to control heart rate <90 bpm at rest, and monitoring serum creatinine and potassium within 1-2 weeks of medication initiation in hospitalized patients with hypertension, tachycardia, and CKD 1, 2

The European Society of Cardiology recommends targeting blood pressure <130/80 mmHg in all patients with CKD regardless of stage or age, as this reduces cardiovascular mortality and slows kidney disease progression 3, 4, 5, 6
For patients with moderate-to-severe CKD (eGFR >30 mL/min/1.73 m²), the European Society of Cardiology recommends aiming for systolic BP 120-129 mmHg if tolerated, as this provides additional cardiovascular and renal protection 7, 6, 2

The American Journal of Kidney Diseases recommends initiating an ACE inhibitor as first-line therapy for all patients with CKD stage 3 or higher, or stage 1-2 with albuminuria ≥300 mg/d 8, 5, 9, 6, 2
The American Heart Association recommends adding a beta-blocker to control ventricular rate to <90 bpm at rest after addressing reversible causes (pain, fever, volume depletion, hyperthyroidism) 1

The European Heart Journal recommends adding a long-acting dihydropyridine calcium channel blocker (amlodipine 5-10 mg daily) or a thiazide-type diuretic (chlorthalidone 12.5-25 mg daily) as second-line therapy when BP goal is not achieved 2

The American Journal of Kidney Diseases recommends measuring BP at least twice daily during admission (morning and evening) to assess response to therapy, and checking serum creatinine and potassium within 1-2 weeks of initiating or titrating ACE inhibitor/ARB 1, 8, 2

The European Heart Journal recommends measuring serum creatinine, eGFR, and urine albumin-to-creatinine ratio in all patients with hypertension and CKD, and obtaining 12-lead ECG to assess for left ventricular hypertrophy, atrial fibrillation, or other arrhythmias causing tachycardia 3, 4

The European Heart Journal recommends initial antihypertensive treatment should include a thiazide-type diuretic or calcium channel blocker, either alone or in combination with an ACE inhibitor/ARB for black patients 7, 5

The American College of Physicians recommends referring to nephrology if eGFR <30 mL/min/1.73 m², rapidly progressive kidney disease (>30% decline in eGFR within 4 weeks), or uncertainty about CKD etiology 1

The American Journal of Kidney Diseases recommends scheduling clinic follow-up every 6-8 weeks until BP goal is safely achieved, and once target BP is achieved, laboratory monitoring and clinic follow-up should occur every 3-6 months 8